{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-119095","form_type":"8-K","ticker":"GPCR","cik":"0001888886","company_name":"Structure Therapeutics Inc.","filed_at":"2025-12-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.987207+00:00","generated_at":"2026-05-16T14:05:45.028369+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Structure Therapeutics reports positive Phase 2 data for oral GLP-1 aleniglipron; plans Phase 3 by mid-2026","bullets":["Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) at 120 mg in Phase 2b ACCESS study; up to 15.3% (35.5 lbs) at 240 mg in exploratory ACCESS II.","No AE-related discontinuations when starting at 2.5 mg in OLE and body composition studies, improving tolerability vs 5 mg start.","No cases of drug-induced liver injury, persistent liver enzyme elevations, or QTc prolongation across all aleniglipron studies.","Plans to request Type B End-of-Phase 2 meeting with FDA in H1 2026; Phase 3 program initiation expected by mid-2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-119095","json":"https://secwatch.observer/filing/0001104659-25-119095.json","markdown":"https://secwatch.observer/filing/0001104659-25-119095.md","text":"https://secwatch.observer/filing/0001104659-25-119095.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1888886/000110465925119095/0001104659-25-119095-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1888886/000110465925119095/tm2532078d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T14:05:45.028369+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}